Utility of QuantiFERON-TB In-Tube Test for Differentiating Active Tuberculosis  from Latent Tuberculosis Infection in an Intermediate Burden Country by 源�紐낆닔 et al.
1)
INTRODUCTION
In the early 2000s, in vitro blood tests measuring pro-
duction of interferon (IFN)-γ by T-cells exposed to
antigens highly specific to the Mycobacterium tuberculo-
sis antigens ESAT-6 and CFP-10 were introduced to
detect latent tuberculosis infection (LTBI). These included
a whole-blood IFN-γ enzyme-linked immunosorbent as-
say (ELISA) and an enzyme-linked immunospot assay
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(ELISPOT), collectively referred to as IFN-γ release
assays (IGRAs) (1). Unlike the tuberculin skin test (TST),
which had been the only diagnostic tool for LTBI since
the early 1930s, IGRAs are not affected by prior Bacille
Calmette-Guerin (BCG) vaccination nor by nontuber-
culous mycobacteria (NTM) infection (with the exception
of Mycobacterium kansasii, Mycobacterium szulgai, and
Mycobacterium marinum), thus yielding greater speci-
ficity than TST (2). Promising results in the diagnosis of
LTBI and active tuberculosis (TB) infection by both tests
have been reported (3-9). On the basis of these data, the
U.S. Food and Drug Administration approved the use of
a commercialized whole-blood interferon-γ ELISA as-
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say, QuantiFERON-TB Gold (QFT-G; Cellestis, Carne-
gie, Australia), for the diagnosis of active TB and LTBI
(10). A commercialized ELISPOT assay, T-SPOT.TB as-
say (Oxford Immunotec, Oxford, UK), was also approved
for diagnostic use in Europe (11, 12).
One concern in routine clinical practice is to distin-
guish patients with active TB from LTBI. Several studies
have reported that IFN-γ production by lymphocytes
challenged by M. tuberculosis-specific antigens was
proportional to M. tuberculosis activity (13-17). Goletti et
al. compared the results of different IGRAs in patients
with clinically suspected TB according to outcome: cul-
ture-proven TB versus alternative diagnosis established
or resolution of clinical symptoms without drugs active
against TB (15). In that study, IFN-γ levels measured
using whole blood enzyme-linked immunosorbent assay
were significantly higher in patients with active TB than
TST-positive or negative controls. However, the quanti-
tative results of either T-SPOT.TB or QuantiFERON-TB
Gold were not reported.
It was, therefore, hypothesized that by using the
QuantiFERON-TB Gold In-Tube (QFT-IT) test, which is
a more advanced test than QFT-G (18), it would be
possible to establish the threshold IFN-γ levels, per-
mitting the distinction of active TB from LTBI. Thus, a
study was designed to compare IFN-γ levels of QFT-IT
between active TB and LTBI patients admitted to Se-
verance Hospital (Seoul, South Korea) between July 2006
and August 2007. The incidence of active TB in South
Korea is intermediate (96/105 cases per year), and BCG
vaccination at birth has been mandatory (19).
MATERIALS AND METHODS
1. Study design
Records of 314 patients older than 15 years who had
QFT-IT performed because of suspected LTBI or active
TB between July 2006 and August 2007 at Severance
Hospital, Yonsei University College of Medicine (a 2000-
bed tertiary care teaching hospital), were reviewed retro-
spectively. The study was approved by the local research
ethics committee. The following data were collected by
reviewing the records: results of QFT-IT, results of
acid-fast stain and Mycobacterium culture, pathology
results, chest X-ray findings, other medical conditions,
and treatments given. We compared IFN-γ levels of
QFT-IT between individuals with active TB and LTBI
before anti-TB treatment.
2. QFT-IT
Peripheral venous blood was collected into three ev-
acuated QFT-IT tubes, one containing TB antigens
(ESAT-6, CFP-10, and TB 7.7), a positive control tube
containing phytohemagglutinin, and a negative control
tube, and processed for 4 hours. ELISA for IFN-γ was
performed according to the manufacturers instructions.
Samples were incubated for 20 hours. A positive result
was defined as TB antigen minus negative control IFN-γ
equal to or greater than 0.35 IU/mL and increment of
negative control IFN-γ level to 25% or more. An inde-
terminate result was defined as either a negative control
IFN-γ level of >8.0 IU/mL or a positive control IFN-γ
response of <0.5 IU/mL with a TB antigen minus a ne-
gative control IFN-γ level of either <0.35 IU/mL or <25%
of the negative control value. Because the IFN-γ ELISA
cannot accurately quantify levels greater than 10 IU/mL,
such levels were treated as 10 IU/mL during analysis.
3. Definitions and diagnoses
1) Active TB
Final diagnoses were made on the basis of all the cli-
nical, radiological, microbiological, and pathological in-
formation collected. Active TB was defined as culture
positive for TB (culture confirmed TB), diagnosed his-
tologically, or obvious symptoms and signs appropriate for
diagnosis, which responded clinically and radiologically to
a full course of first-line anti-TB drugs (clinical TB).
2) Immunocompromised subjects
Immunocompromised subjects were defined as those
with hematological malignancy, aplastic anemia, chronic
renal failure, primary immunodeficiency diseases, HIV in-
fection or those receiving immunosuppressive drugs (anti-
cancer chemotherapy, post-transplantation, receiving >15
mg/day prednisolone for >1 month).
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3) LTBI subjects
LTBI subjects were defined as patients with positive
result of QFT-IT and without evidence of active tuber-
culosis.
4) High risk LTBI
Patients with high risk LTBI were defined as patients
with a history of active TB or TB contact or old TB
lesions on chest X-ray.
5) Statistical analysis
Differences in QFT-IT-measured IFN-γ levels be-
tween two groups were analyzed using a two sample t-
test. P values of <0.05 were considered significant. All
analyses were performed using SPSS for Windows (Ver-
sion 12.0).
RESULTS
Of the 314 persons screened for this study, 158 persons
were eligible. The number of active TB patients and LTBI
patients was 82 and 76, respectively. The result of QFT-
IT was positive in 66 of 82 (80.5%) patients, negative in
15 of 82 (18.3%) patients, and indeterminate in 1 of 82
(1.2%) patients with active TB. Of the 76 LTBI patients,
those with high risk for LTBI were 29 patients (38.1%).
Of the 82 active TB patients, one patient was excluded
because of indeterminate QFT-IT result. Baseline charac-
teristics for the remaining 157 patients are shown in Table
1. Of the 81 remaining active TB patients, 38 patients
(38/81, 46.9%) had culture-confirmed pulmonary TB, 2
patients (2/81, 2.5%) had culture-confirmed extrapulmo-
nary TB, 31 patients (31/81, 38.3%) had Clinical pul-
monary TB, and 10 patients (10/81, 12.3%) had Clinical
extrapulmonary TB.
1. Active TB vs. LTBI
Subjects with active TB (n=81) and LTBI (n=76) were
included. Mean±SD IFN-γ levels were 4.96±3.98 IU/mL
(range 0.08-10) for subjects with active TB and 4.11±3.57
IU/mL (range 0.35-10) for subjects with LTBI. The
quantitative results of QFT-IT on IFN-γ levels between
all the subjects with active TB and those with LTBI were
not statistically significant (P=0.16).
2. Culture confirmed active TB vs. LTBI
In subjects with culture confirmed active TB (n=40),
mean±SD IFN-γ level was 4.54±4.05 IU/mL (range-
0.08-10). The difference on the quantitative results of the
QFT-IT between subjects with culture confirmed active
TB and those of LTBI was also statistically insignificant
(P=0.554) (Fig. 1B).
Table 1. Baseline Characteristics of Subjects
Variables Active TB (n=81) LTBI (n=76) P value
Age, years (Mean±SD)
Male n (%)
Underlying disease, n (%)
Diabetes mellitus
Chronic renal failure
Autoimmune disease
Post-transplantation status
HIV infection
Solid cancer
Hematologic malignancy
Immunodeficiency disease
Other*
None
Combined disease†
Immunocompromised subjects, n (%)
47.27±18.33
42 (51.9)
6 ( 7.4)
0 ( 0)
3 ( 3.7)
0 ( 0)
1 ( 1.2)
2 ( 2.5)
1 ( 1.2)
1 ( 1.2)
10 (12.3)
55 (67.9)
2 ( 2.5)
6 ( 7.4)
53.57±14.13
40 (52.6)
5 ( 6.6)
3 ( 3.9)
9 (11.8)
1 ( 1.3)
1 ( 1.3)
6 ( 7.9)
2 ( 2.6)
0 ( 0)
15 (19.7)
33 (43.4)
1 ( 1.3)
11 (14.5)
0.017
0.922
NA
-
-
-
-
-
-
-
-
-
-
-
0.154
Abbreviations : TB, tuberculosis; LTBI, Latent tuberculosis infection; NA, Not analyzed using statistics
*Other diagnoses encompass chronic heart or vascular disease, chronic lung disease, and benign tumors
†Combined disease encompasses the diagnosis of more than one of the following diseases: diabetes mellitus, chronic renal failure, autoimmune
disease, post-transplantation status, HIV infection, solid cancer, hematologic malignancy, aplastic anemia, and immunodeficiency.
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DISCUSSION
The aim of the present study was to determine whether
quantitative analysis using QFT-IT could differentiate
between active TB and LTBI. The quantitative results of
the QFT-IT of subjects with active TB (culture confirm-
ed TB and clinical TB) were not higher than those with
LTBI. Our results showed that there was no relationship
between the activity of M. tuberculosis infection and the
production of IFN-γ by lymphocytes, as assessed by
QFT-IT. The result of the present study wasnt consis-
tent with that of several studies that have reported that
IFN-γ production by lymphocytes challenged with M.
tuberculosis-specific antigens was proportional to M.
tuberculosis activity (13-17). There was another report
about the use of IGRAs in distinguishing active TB from
LTBI (17). In that study, mean (range) sfu number of
subjects with active TB was 107.4±56.0 (1-207), that of
subjects with LTBI with a TST induration diameter of >5
mmwas 53.6±60.3 (7-239), and that of subjects with LTBI
with a TST induration diameter of ≤5 mm was 18.9±27.1
(7-143). Mean sfu numbers of active TB were statistically
different from that of LTBI with a TST induration diameter
of >5 mm and those of LTBI with a TST induration
diameter of ≤5 mm. The authors assessed the cut-off
value of sfu, measured by T.SPOT.TB, to distinguish
active TB from LTBI. In that study, the T.SPOT.TB has
a sensitivity of 82.8% and specificity of 74.2% for dis-
tinguishing active TB from LTBI at a threshold of 49 sfu.
Discrepancy between results of that study and those of the
present study might be explained by several factors. First,
in that study, LTBI was defined as the positive result of
T.SPOT.TB without clinical or radiological evidence of TB
but we defined LTBI as the positive QFT-IT without
evidence of active TB. Second, the authors compared the
values of sfu, measured by T.SPOT.TB between culture-
positive TB and LTBI but we compared the IFN-γ levels,
measured by QFT-IT. Because the IFN-γ ELISA cannot
accurately quantify values of more than 10 IU/ml, such
inaccuracy might be another factor. Other reports in Korea
have explored the use of IGRAs in the diagnosis of active
TB. Lee et al. studied 87 subjects with active TB (culture
proven in 63%) and 131 young students with low risk of
LTBI. Sensitivity of 86.2% (95% CI, 77.1-92.7) and speci-
ficity of 87.0% (95% CI, 80.0-92.2) at a threshold of 0.13
IU/mL for QFT-G in the diagnosis of active TB were
reported (13). Kang et al. studied 144 subjects with
suspected pulmonary TB. They reported 49% specificity
(95% CI, 37-61) and 89% sensitivity (95% CI, 79-96) at
a threshold of 0.35 IU/mL for QFT-G in the diagnosis of
active pulmonary TB (20). The association of these results
is debatable because the definition of LTBI is arbitrary and
the exact proportions of LTBI in two reports are unknown.
To our knowledge, the present study is the first study
to determine whether quantitative analysis using QFT-IT
Figure. 1. Dot plots showing IFN-γ levels measured by QFT-IT. (A) IFN-γ levels of active TB (n=81) and LTBI (n=76),
(B) culture confirmed active TB (n=40) and LTBI (n=76). Each dot represents an individual subject. Abbreviations : TB,
tuberculosis; LTBI, latent tuberculosis infection.
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can discriminate between active TB and LTBI in an
intermediate-burden country. However, the present study
had several limitations. First, the definition of LTBI was
arbitrary. In reality, we define LTBI as patients with po-
sitive result of QFT-IT without evidence of active
tuberculosis. Because an arbitrary definition was used to
define LTBI in the present study (positive QFT-IT result
without evidence of active TB), LTBI patients defined in
the present study might not have included LTBI patients
with negative results with QFT-IT but might have in-
cluded healthy individuals with positive results of QFT-
IT instead. Because there is no gold standard for the
diagnosis of LTBI, it was difficult to resolve this limi-
tation. Second, the present study is retrospective; we
evaluated the subjects based on clinical records. For some
subjects, there was no BCG vaccination history. So the
effect of BCG vaccination on QFT-IT results remains
unresolved. Because it is known that QFT-G is minimally
affected by BCG vaccination, we presumed that the
QFT-IT results in the present study also might have been
minimally affected (2).
In summary, we showed that the production of IFN-γ
measured by QFT-IT showed no correlation between its
level and the activity of M. tuberculosis infection. These
results suggest that measuring IFN-γ using QFT-IT
might not be useful for distinguishing active TB from
LTBI. A large, prospective study will be necessary to
confirm that patients with high IFN-γ levels are not at
higher risk of having active TB.
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